Last reviewed · How we verify
Interferon-gamma, Recombinant
Recombinant interferon-gamma activates macrophages and enhances immune cell function to boost the body's antiviral and antimicrobial defenses.
Recombinant interferon-gamma activates macrophages and enhances immune cell function to boost the body's antiviral and antimicrobial defenses. Used for Chronic granulomatous disease, Severe malaria infection.
At a glance
| Generic name | Interferon-gamma, Recombinant |
|---|---|
| Sponsor | Radboud University Medical Center |
| Drug class | Cytokine |
| Target | Interferon-gamma receptor (IFNGR) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Interferon-gamma (IFN-γ) is a cytokine produced by T cells and natural killer cells that acts as a key regulator of innate and adaptive immunity. It binds to interferon-gamma receptors on immune cells, particularly macrophages, enhancing their microbicidal and tumoricidal activity. The recombinant form is used therapeutically to augment immune responses in conditions characterized by immune deficiency or dysregulation.
Approved indications
- Chronic granulomatous disease
- Severe malaria infection
Common side effects
- Fever
- Headache
- Myalgia
- Fatigue
- Injection site reactions
Key clinical trials
- Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor (PHASE3)
- Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial (PHASE2)
- Effect of Interferon Gamma as a Treatment for Post-aggressive Immunosuppression in Intensive Care Units, a Randomized Bayesian Double-blind Controlled Trial Versus Placebo (PHASE2, PHASE3)
- Human Recombinant Interferon Gamma in the Treatment of Ventilator-acquired Pneumonia in ICU Patients (PHASE3)
- Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation (PHASE2)
- Safety and Immunogenicity Study of Na-GST-1 With or Without CpG (PHASE1)
- Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast Cancer (PHASE1, PHASE2)
- Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Interferon-gamma, Recombinant CI brief — competitive landscape report
- Interferon-gamma, Recombinant updates RSS · CI watch RSS
- Radboud University Medical Center portfolio CI